A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Forero-Torres, Andres [1 ]
Bartlett, Nancy L. [2 ]
Nasta, Sunita D. [3 ]
Northfelt, Donald [4 ]
Beaven, Anne [5 ]
Myint, Han [6 ]
Whiting, Nancy C. [7 ]
Drachman, Jonathan G. [7 ]
Moskowitz, Craig H. [8 ]
机构：
[1] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[3] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Mayo Clin Arizona, Scottsdale, AZ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] Univ Colorado, Aurora, CO USA
[7] Seattle Genet Inc, Bothell, WA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：243 / 244
页数：2
相关论文
共 50 条
  • [41] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [42] Management of Relapsed Diffuse Large B-cell Lymphoma
    Crump, Michael
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (06) : 1195 - +
  • [43] Management of Relapsed Diffuse Large B-Cell Lymphoma
    Kenkre, Vaishalee Padgaonkar
    Smith, Sonali M.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (05) : 393 - 403
  • [44] A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Roschewski, Mark
    Munugalavadla, Veerendra
    Nuttall, Barrett
    Burke, Kathleen
    Acar, Melih
    White, Rafael
    Udriste, Maria
    Sharma, Shringi
    Dougherty, Brian
    Flinn, Ian
    Saba, Nakhle S.
    Reagan, Patrick M.
    de Vos, Sven
    Arkenau, Hendrik-Tobias
    Collins, Graham P.
    Mortlock, Andrew
    Patel, Manish R.
    BLOOD, 2021, 138
  • [45] Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma
    Barnes, Jeffrey A.
    Jacobsen, Eric
    Feng, Yang
    Freedman, Arnold S.
    Hochberg, Ephraim P.
    LaCasce, Ann S.
    Armand, Philippe
    Joyce, Robin
    Neuberg, Donna
    Fisher, David C.
    Abramson, Jeremy S.
    BLOOD, 2011, 118 (21) : 710 - 711
  • [46] Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Triguero, Ana
    Banerjee, Lalita
    Mcmillan, Andrew
    Seymour, Erlene
    Hirata, Jamie
    de Guzman, Jayson
    Sharma, Sunil
    Jin, Hyun Yong
    Musick, Lisa
    Diefenbach, Catherine
    LANCET HAEMATOLOGY, 2024, 11 (02): : e136 - e146
  • [47] Management of relapsed diffuse large B-cell lymphoma
    Vaishalee Padgaonkar Kenkre
    Sonali M. Smith
    Current Oncology Reports, 2008, 10 : 393 - 403
  • [48] Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma
    Yun Hou
    Hua-qing Wang
    Yi Ba
    Medical Oncology, 2012, 29 : 2409 - 2416
  • [49] Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial
    Witzens-Harig, Mathias
    Keller, Ulrich
    Viardot, Andreas
    Buske, Christian
    Crombe, Anne
    Hoenig, Elisabeth
    Meissner, Julia
    Ho, Anthony D.
    Marks, Reinhard
    Dreyling, Martin H.
    Hess, Georg
    BLOOD, 2015, 126 (23)
  • [50] Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma
    Hou, Yun
    Wang, Hua-qing
    Ba, Yi
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2409 - 2416
12345